Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy. (January 2019)

• Record Type: Journal Article
• Authors: Cheng, Hong; Zheng, Rong-Rong; Fan, Gui-Ling; Fan, Jing-Hao; Zhao, Lin-Ping; Jiang, Xue-Yan; Yang, Bin; Yu, Xi-Yong; Li, Shi-Ying; Zhang, Xian-Zheng
• Is Part Of: Biomaterials. Volume 188(2018)
• Page Start: 1
• Page End: 11
• Publication Date: 2019-01
• Subjects: Self-delivery -- Dual-target -- Plasma membrane -- Mitochondria -- Photodynamic therapy; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2018.10.005
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Mitochondria and cell membrane play important roles in maintaining cellular activity and stability. Here, a single-agent self-delivery chimeric peptide based nanoparticle (designated as M-ChiP) was developed for mitochondria and plasma membrane dual-targeted photodynamic tumor therapy. Without additional carrier, M-ChiP possessed high drug loading efficacy as well as the excellent ability of producing reactive oxygen species (ROS). Moreover, the dual-targeting property facilitated the effective subcellular localization of photosensitizer protoporphyrin IX (PpIX) to generate ROS in situ for enhanced photodynamic therapy (PDT). Notably, plasma membrane-targeted PDT would enhance the membrane permeability to improve the cellular delivery of M-ChiP, and even directly disrupt the cell membrane to induce cell necrosis. Additionally, mitochondria-targeted PDT would decrease mitochondrial membrane potential and significantly promote the cell apoptosis. Both in vitro and in vivo investigations indicated that this combinatorial PDT in mitochondria and plasma membrane could achieve the therapeutic effect maximization with reduced side effects. The single-agent self-delivery system with dual-targeting strategy was demonstrated to be a promising nanoplatform for synergistic tumor therapy.